Attachment A3. Hazardous Meds.pdf

This is an attachment document supporting a state and local contract opportunity issued by Springfield Hospital Center in Maryland for pharmaceutical hazardous waste pickup and disposal services. The attachment provides a comprehensive list of hazardous drugs and medications currently used within the facility that require special handling and disposal. The contract opportunity spans three years, from 2026 through 2029, and requires vendors to provide regular and as-needed pharmaceutical special (regulated) medical waste and pharmaceutical hazardous drug waste pickup and disposal services.

Attachment A identifies three categories of hazardous substances used at Springfield Hospital Center: antineoplastic drugs (including flutamide, letrozole, leuprolide, and megestrol), non-antineoplastic hazardous drugs (including abacavir, carbamazepine, divalproex, estrogen/progestin combinations, liraglutide, medroxyprogesterone, oxcarbazepine, phenytoin, and spironolactone), and non-antineoplastic drugs with adverse reproductive effects (including clonazepam, dutasteride, finasteride, fluconazole, paroxetine, topiramate, tretinoin, valproic acid, and ziprasidone). This inventory of hazardous medications establishes the scope of pharmaceutical waste materials that selected vendors must be equipped to handle, transport, and dispose of in compliance with applicable regulatory requirements.